Alzheimer's disease and its management in the year 2010

被引:30
作者
Cummings, JL
Jeste, DV
机构
[1] Univ Calif Los Angeles, Dept Neurol, Sch Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Psychiat, Sch Med, Los Angeles, CA 90095 USA
[3] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
关键词
D O I
10.1176/ps.50.9.1173
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
By 2010 the number of cases of Alzheimer's disease and other dementias will have increased by at least 25 percent. Alzheimer's disease poses an enormous threat to health service and public health resources. Three areas that require targeted research are early detection and recognition, biological markers and diagnosis, and pharmacotherapy. Care of patients with Alzheimer's disease in managed care organizations must be improved through a combination of research, education, advocacy, and legislation. Research in the pathogenic cascade of events within the brain leading to Alzheimer's disease has advanced, and treatment targets within the steps of the process have been specified. The current drug discovery and testing infrastructure is insufficient for major advances in therapy by 2010, Strategies for achieving an optimum outcome by then include increased funding of targeted research; expansion of drug discovery and therapeutic testing efforts; increased training of basic, clinical, and translational scientists; and study of optimum health care delivery systems.
引用
收藏
页码:1173 / 1177
页数:5
相关论文
共 36 条
[1]   DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS DECREASE THE RISK FOR ALZHEIMERS-DISEASE - THE ROTTERDAM STUDY [J].
ANDERSEN, K ;
LAUNER, LJ ;
OTT, A ;
HOES, AW ;
BRETELER, MMB ;
HOFMAN, A .
NEUROLOGY, 1995, 45 (08) :1441-1445
[2]   Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[3]   DOCUMENTATION AND EVALUATION OF COGNITIVE IMPAIRMENT IN ELDERLY PRIMARY-CARE PATIENTS [J].
CALLAHAN, CM ;
HENDRIE, HC ;
TIERNEY, WM .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (06) :422-429
[4]   Metrifonate treatment of the cognitive deficits of Alzheimer's disease [J].
Cummings, JL ;
Cyrus, PA ;
Bieber, F ;
Mas, J ;
Orazem, J ;
Gulanski, B .
NEUROLOGY, 1998, 50 (05) :1214-1221
[5]   Alzheimer's disease - Etiologies, pathophysiology, cognitive reserve, and treatment opportunities [J].
Cummings, JL ;
Vinters, HV ;
Cole, GM ;
Khachaturian, ZS .
NEUROLOGY, 1998, 51 (01) :S2-S17
[6]   PREVALENCE OF ALZHEIMERS-DISEASE IN A COMMUNITY POPULATION OF OLDER PERSONS - HIGHER THAN PREVIOUSLY REPORTED [J].
EVANS, DA ;
FUNKENSTEIN, H ;
ALBERT, MS ;
SCHERR, PA ;
COOK, NR ;
CHOWN, MJ ;
HEBERT, LE ;
HENNEKENS, CH ;
TAYLOR, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (18) :2551-2556
[7]   A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE [J].
FARLOW, M ;
GRACON, SI ;
HERSHEY, LA ;
LEWIS, KW ;
SADOWSKY, CH ;
DOLANURENO, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18) :2523-2529
[8]  
Ferrar P., 1987, Entomonograph, V8, P1
[9]  
Finkel S I, 1996, Int Psychogeriatr, V8 Suppl 3, P497
[10]   MILD COGNITIVE IMPAIRMENT IN THE ELDERLY - PREDICTORS OF DEMENTIA [J].
FLICKER, C ;
FERRIS, SH ;
REISBERG, B .
NEUROLOGY, 1991, 41 (07) :1006-1009